Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $50.83 Consensus PT from Analysts
Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) have been assigned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average […]
More Stories
Parks! America, Inc. (OTCMKTS:PRKA) Short Interest Down 35.3% in September
Parks! America, Inc. (OTCMKTS:PRKA – Get Free Report) was the target of a large decline in short interest in the...
Dimensional Global ex US Core Fixed Income ETF (NASDAQ:DFGX) Short Interest Up 74.1% in September
Dimensional Global ex US Core Fixed Income ETF (NASDAQ:DFGX – Get Free Report) saw a significant growth in short interest...
iShares iBonds Dec 2031 Term Treasury ETF (NASDAQ:IBTL) Short Interest Update
iShares iBonds Dec 2031 Term Treasury ETF (NASDAQ:IBTL – Get Free Report) was the recipient of a significant increase in...
Leafly Holdings, Inc. (NASDAQ:LFLYW) Sees Significant Decrease in Short Interest
Leafly Holdings, Inc. (NASDAQ:LFLYW – Get Free Report) was the target of a large decline in short interest during the...
Eaton Vance Short Duration Income ETF (NASDAQ:EVSD) Sees Significant Increase in Short Interest
Eaton Vance Short Duration Income ETF (NASDAQ:EVSD – Get Free Report) saw a large growth in short interest in September....
Impala Platinum Holdings Limited (OTCMKTS:IMPUY) Short Interest Update
Impala Platinum Holdings Limited (OTCMKTS:IMPUY – Get Free Report) was the recipient of a large increase in short interest during...